Induction of unresponsiveness limits tumor protection by adoptively transferred MDM2-specific cytotoxic T lymphocytes

被引:24
作者
Bendle, GM
Holler, A
Pang, LK
Hsu, S
Krampera, M
Simpson, E
Stauss, HJ
机构
[1] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Immunol, London W12 0NN, England
[2] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Transplantat Biol Sect, MRC Clin Sci Ctr, London W12 0NN, England
关键词
D O I
10.1158/0008-5472.CAN-04-0630
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
There is evidence showing that high avidity CTLs can be more effective than low avidity CTLs for adoptive tumor immunotherapy. Because many T cell-recognized tumor antigens are nonmutated self-proteins, tolerance mechanisms are likely to render high avidity T cells unresponsive or cause T cell elimination by clonal deletion. We recently used the allo-restricted strategy to circumvent immunologic tolerance to a ubiquitously expressed tumor-associated protein, MDM2, and raised high avidity CTLs in humans and in mice. In this study, we investigated whether high avidity MDM2-specific CTLs can mediate tumor protection without causing damage to normal tissues in mice. Although the CTLs prolonged survival of tumor-bearing mice without causing damage to normal tissues, tumor protection was incomplete. We show that tumor growth occurred despite the continued presence of MDM2-specific CTLs and the continued susceptibility of tumor cells to CTL killing. However, analysis of the CTLs revealed that they had been rendered unresponsive in vivo because they did not produce interferon gamma in response to antigen-specific stimulation. These experiments suggest that induction of unresponsiveness may be an important mechanism limiting the efficacy of adoptive CTL therapy.
引用
收藏
页码:8052 / 8056
页数:5
相关论文
共 36 条
[1]   REVERSAL OF INVITRO T-CELL CLONAL ANERGY BY IL-2 STIMULATION [J].
BEVERLY, B ;
KANG, SM ;
LENARDO, MJ ;
SCHWARTZ, RH .
INTERNATIONAL IMMUNOLOGY, 1992, 4 (06) :661-671
[2]  
Dahl AM, 1996, J IMMUNOL, V157, P239
[3]  
Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514
[4]   CYTOTOXIC T-LYMPHOCYTES RAISED AGAINST A SUBDOMINANT EPITOPE OFFERED AS A SYNTHETIC PEPTIDE ERADICATE HUMAN PAPILLOMAVIRUS TYPE 16-INDUCED TUMORS [J].
FELTKAMP, MCW ;
VREUGDENHIL, GR ;
VIERBOOM, RPM ;
RAS, E ;
VANDERBURG, SH ;
TERSCHEGGET, J ;
MELIEF, CJM ;
KAST, WM .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1995, 25 (09) :2638-2642
[5]  
Freedman DA, 1999, CANCER RES, V59, P1
[6]  
Ganss R, 2002, CANCER RES, V62, P1462
[7]   The risk of autoimmunity associated with tumor immunotherapy [J].
Gilboa, E .
NATURE IMMUNOLOGY, 2001, 2 (09) :789-792
[8]   Eradication of established tumors by CD8+ T cell adoptive immunotherapy [J].
Hanson, HL ;
Donermeyer, DL ;
Ikeda, H ;
White, JM ;
Shankaran, V ;
Old, LJ ;
Shiku, H ;
Schreiber, RD ;
Allen, PM .
IMMUNITY, 2000, 13 (02) :265-276
[9]   The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation [J].
Hill, GR ;
Ferrara, JLM .
BLOOD, 2000, 95 (09) :2754-2759
[10]   In vitro evolution of a T cell receptor with high affinity for peptide/MHC [J].
Holler, PD ;
Holman, PO ;
Shusta, EV ;
O'Herrin, S ;
Wittrup, KD ;
Kranz, DM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (10) :5387-5392